What Were Pfizer’s Major Achievements in 2016?


Nov. 20 2020, Updated 2:33 p.m. ET

Pfizer’s key approvals in 2016

During 2016, Pfizer (PFE) succeeded in expanding its label for Ibrance, its breast cancer treatment. Ibrance received approval for recurrent breast cancer in the US. For more information on Ibrance, read Ibrance Is the Only Registered CDK 4/6 Inhibitor for Breast Cancer.

Additionally, Xalkori won a second approval for the indication of ROS-positive NSCLC (non-small-cell lung carcinoma). Pfizer is exploring the drug for the third indication of MET-positive lung cancer. The company also improved dosing for Xeljanz with approved once-a-day formulation in the US. For detailed information on Xeljanz, read Will Sales of Xeljanz Offset Falling Sales of Enbrel?

Article continues below advertisement

Notably, Pfizer’s Prevnar 13 won approval for use in infants in China to prevent pneumococcal disease. However, Pfizer expects slightly lower revenues for Prevnar 13 in 2016 compared to 2015. After its launch in 4Q14, Prevnar 13 captured the market at a very fast pace. Perhaps the smaller remaining opportunity accounts for the fall in revenue in 2016.

Pfizer’s submissions in 2016

Of the four submissions in 2016, Inotuzumab and Mylotarg are antibody drug conjugates for treating liquid tumors. The third candidate, Avelumab, is being developed in association with Merck, while the company might submit ertugliflozin for approval at the end of 2016. Avelumab, which seems to be an important driver for Pfizer’s revenues over the next one to five years, will compete with Bristol-Myers Squibb’s (BMY) Opdivo, Roche’s (RHHBY) Tecentriq, and Merck’s (MRK) Keytruda.

To avoid volatility and the direct risk associated with Pfizer, you can invest in ETFs such as the Health Care Select Sector SPDR ETF (XLV). The ETF invests 7.5% in Pfizer.


More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.